cells in leukapheresis collections. [4][5] [6] [7] Therefore, the use of in vitro purging techniques is now considered a major issue in PBPC-based autografting procedures. Peripheral blood leukocytes are becoming the preferred source of hematopoietic progenitor/stem cells for Applying in vitro purging techniques to blood-derived progenitors, a few specific problems have emerged, mainly autologous transplantation. However, in vitro purging procedures are complex and expensive when applied to related to the large quantities of cells. Indeed, two to four leukapheresis collections are usually required to harvest peripheral blood progenitor cells harvests. This is mainly due to the large quantities of nucleated cells enough progenitors for safe engraftment. 2, 8, 9 This implies a two-to five-fold increase in the total cellularity compared present in leukapheresis collections. Aiming to reduce total cellularity without significant loss of CD34 + cells, to BM collections. The large amounts of cells to be processed make any purging procedure cumbersome and we developed an in vitro cell separation procedure based on ficoll/metrizoate gradient used at a final density of highly expensive, particularly those based on immunomagnetic methods. 10 1.067 g/ml. To obtain this density, standard Lymphoprep (1.077 g/ml) was diluted with normal saline solIn this study we describe a simple procedure, based on a modified ficoll-metrizoate gradient separation, that was ution (NaCl 9 g/l). Twenty-six leukapheresis collections (median cellularity 21.1 × 10 9 , range 2.8-60) from 14 employed to enrich progenitor cells leukapheresis collections. The gradient separation allowed a marked reduction patients with non-Hodgkin's lymphoma, multiple myeloma or plasma cell leukemia were processed (median of total cellularity, with enrichment and minimal loss of hematopoietic progenitors. The technique also allowed a two leukaphereses per patient). Mean (؎ s.d.) recovery of total nucleated cells, CD34
, range 2.8-60) from 14 employed to enrich progenitor cells leukapheresis collections. The gradient separation allowed a marked reduction patients with non-Hodgkin's lymphoma, multiple myeloma or plasma cell leukemia were processed (median of total cellularity, with enrichment and minimal loss of hematopoietic progenitors. The technique also allowed a two leukaphereses per patient). Mean (؎ s.d.) recovery of total nucleated cells, CD34
+ cells and CFU-GM was partial removal of contaminating neoplastic cells. Both observations indicate that our approach is a useful, 20.9 ؎ 10%, 74.7 ؎ 22% and 70.5 ؎ 19%, respectively. Cumulative per patient progenitor cell recovery was preliminary step prior to immunological purging. always above 50%, and as high as 80% in 10/14 patients, while total cellularity was reduced to a median 21.5% (10-33%) of pre-separation values. Contaminat-
Materials and methods ing neoplastic cells, identified by immunofluorescence in five collections, were reduced by 1-2 logs. The results
Patients and treatments indicate that our density gradient separation is an effective method to reduce total cellularity prior to immunoLeukapheresis products from 15 patients, collected after a high-dose chemotherapy regimen, were processed in vitro. logical purging, without significant loss of progenitor cells.
Eleven patients had a B cell non-Hodgkin's lymphoma (NHL), two had multiple myeloma (MM), and two a Keywords: leukapheresis; progenitor cells; density gradient; autotransplantation plasma cell leukemia (PL). NHL patients were part of a pilot study aimed to evaluate the efficacy of high-dose chemotherapy and autograft with in vitro purged hematopoietic cells in follicular and mantle-cell NHL (manuscript in Mobilized peripheral blood progenitor cells (PBPC) are preparation). All patients gave informed consent to in vitro increasingly used for autograft purposes.
1-3 However, manipulation of their leukapheresis products. highly sensitive molecular or immunological techniques
The high-dose chemotherapy regimen was designed have shown the frequent presence of residual neoplastic according to the original sequential HDS scheme, 11, 12 obtained by multiplying the percentage of CD34 + cells in the whole leukocyte population by the total number of leukocytes in 1 l of blood. The same procedure was employed to evaluate the proportion of CD34 + cells among leukocytes collected by apheresis. In two patients with PL, Results CD38 (Becton Dickinson) and CD138 MoAb (Serotech, Oxford, UK) were used to detect residual plasma cells in Separation on Lymphoprep at different dilutions: results apheresis collections. Plasma cells were identified because on small volume samples of high density CD38 antigen and CD138 antigen coexPure Lymphoprep (1.077 g/ml) allowed a near complete pression. In patient PA, with NHL coexpressing CD19 and recovery of CD34 + cells but removed a median 30% of CD5 antigens, CD19 (Becton Dickinson) and CD5 MoAb cells only. Indeed, at morphological examination, unsepar-(Immunotech, Marseille, France) were employed to identify ated leukaphereses were mostly constituted by monocytes residual lymphoma cells (low forward and right-angle scat-(30-45%), immature granulopoietic cells (blasts to myeloter cells coexpressing CD19 and CD5 antigens). The absolcytes 10-25%) and lymphocytes (4-15%), with a density ute number of contaminating cells was calculated by multilower than 1.077 g/ml. The use of gradients at progressively plying the total cellularity by the percentage of cells lower density was associated with increasing reduction of expressing the antigenic phenotype described above.
total cellularity (60-90%), while maintaining a satisfactory The quantity of myeloid progenitors in the material recovery (50-100%) of PBPC. before and after the separation procedure was estimated by All data refer to separation procedures performed within CFU-GM evaluation, as described. 15 Briefly, 1-10 × 10 4 1 h of cell collection; processing after longer intervals cells were cultured in two 35-mm Petri dishes (Becton allows platelet and leukocyte aggregate formation, thus Dickinson), each containing 1 ml of Iscove's modified Dulreducing the efficiency of the procedure. Maintenance of becco's medium (GIBCO) with 20% fetal bovine serum temperature at 20 Ϯ 1°C before and during the centrifug-(Hyclone, Logan, UT, USA), 0.3% agar (Difco, Detroit, ation was also critical for optimal enrichment in CD34 + MI, USA) and 10% supernatant of the 5637 cell line, as a cells (data not shown). source of colony-stimulating factors. 16 Colonies containing at least 50 cells were scored after 14 days of incubation.
Large scale separation of leukapheresis products Density gradient separation
Three large scale cell separations were carried out at 1.070 g/ml density (gradient A, ie Lymphoprep solution at 90%). Different density gradients were initially tested on small volume leukapheresis samples. Gradients of progressively Cells from patients GP (both leukaphereses) and GM (first leukapheresis) were processed and virtually all CD34 + cells lower density were prepared by mixing standard (1.077 Contaminating tumor cells could be detected in the leurecovery of 54, 52 and 45% in the three separation prokapheresis products of patients PA with low-grade NHL; cedures, respectively (data not shown). Therefore, the CR and FR with plasma cell leukemia. Lymphoma cells remaining 26 leukapheresis collections were separated on were identified as CD19 + /CD5 + cells while neoplastic 1.067 g/ml density gradient (gradient B, ie Lymphoprep plasma cells were identified as CD38 +++ cells (high-intensolution at 85%). As illustrated in Table 1 , the elevated sity fluorescence), coexpressing CD138 antigen. A marked cellularity in the starting population was markedly reduced, reduction (1-2 logs) in the absolute number of neoplastic to a median 20% of pre-separation value, with a satisfactory cells was recorded following all separation procedures perrecovery of CD34 + cells and CFU-GM (median values 85.5 formed in the three tested patients (Table 3) , while recovery and 76.5%, respectively). Although cell removal and proof normal progenitors reached 60, 86 and 85%, respectgenitor cell recovery were somewhat variable, it must be ively, of pre-separation values. emphasized that a progenitor recovery lower than 50% was recorded only in three separation procedures. Moreover, by adding the results of all separation procedures performed Discussion on each patient, a progenitor cell recovery above 50% was recorded in all cases, with more than 80% recovery in 10/14 patients (Table 2 ). Cumulative removal of total nucleated
The aim of this study was to develop a separation procedure, based on a density gradient, capable of removing at cells remained high, with a final cellularity value ranging between 10 and 33% (median 21.5% of the pre-separation least 75-80% of leukapheresis collection cellularity without significant loss of hematopoietic progenitors. We chose value). Thus, a three-to four-fold enrichment in hematopoietic progenitors was obtained in all patients.
Lymphoprep ficoll/-metrizoate solution as a basic reagent + cells recovered after cell separation. because of its low cost and stability at room temperature PBPC enrichment achieved by our procedure is certainly lower than those obtained with other methods employing as well as its lack of toxicity on hematopoietic cells, as has been proven in BM purging procedures.
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18,19 However, some sequential Lymphoprep and Percoll gradients or monoclonal antibodies. [21] [22] [23] [24] However, our separation technique preliminary experiments showed low efficacy of the commercially available 1.077 g/ml solution in removing mature is simple and does not require sophisticated devices or expensive reagents. nucleated cells present in leukapheresis products. This may be explained by the high content of monocytes and immaFinally, the 1.067 g/ml density gradient proved to be an effective method to reduce tumor contamination. In five ture granulopoietic cells in the population that had to be removed. Therefore, the gradient density was reduced by samples from three patients with immunofluorescencedetectable residual tumor cells, a 1-2 logs neoplastic cell mixing Lymphoprep with different proportions of NSS.
A final 85% Lymphoprep/15% NSS v/v solution gave reduction was documented following low-density gradient separation. The precise degree of neoplastic cell removal the best results in terms of both cellularity reduction and PBPC recovery in large-scale separations. Recovery of should be further investigated in more cases, using molecular biology techniques when residual tumor cells are too more than 75% of PBPC, identified either as CD34
+ cells or as CFU-GM, was obtained in most separations. However, few to be detected by immunofluorescence. However, the combination of high CD34 + cell recovery and reduction of a low progenitor recovery, below 50%, was occasionally observed with the first leukapheresis collection. This could cellularity and neoplastic cell contamination makes our procedure a useful preliminary step prior to PBPC in vitro be ascribed to variations in cell composition among the different collections. In fact, a low CD34 + recovery was purging. almost invariably associated with early recovery from cytopenia and relatively low values of total leukocytes harvested (р10 × 10 9 ). Acknowledgements Low-density gradients showed poor efficiency in the fractionation of BM cell harvests: CD34 + cells were highly
The present study was suppported by 'Associazione Italiana per enriched but their total recovery was variable and unsatisla Ricerca sul Cancro' (AIRC).
factory (data not shown). The discrepancy between mobilized PB cells and BM-derived cells could be explained by differences in progenitor cell density. Thus, our procedure References seems specifically suitable for leukapheresis collections, in particular for those with high cell counts. Indeed, in spite verified.
